Exclusions from RCTs are translated into clinical practice. When the registrational trials exclude groups based on expected safety concerns or no opportunity for benefit, commercial use must stay on the intended population studied in the trials. They know regulatory practice.
‘ In a Trial of Ebola Virus Disease Therapeutics‘, which was testing four different drugs against the Ebola virus, they will find that the safety board pulled Remdesivir out of trial six months early, because over 50% of patients who received it died.
https://t.co/HVmk2BB3W6